stockrow
Friday 6 November 2026
Export PRCT’s income statement to Excel — free account
PROCEPT BioRobotics Corporation
PRCT Healthcare Medical Devices
PROCEPT BioRobotics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $308.1 million, up 37.2% from fiscal 2024.
- Revenue
- +18.0%
- EPS
- −21.1%
- Free cash flow
- −1.57%
- Total debt
- +0.39%
Quarter to September 2026, against a year earlier
20.75
0.48
+2.37%
Follow PRCT
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 4 | 5 |
+8 more TTM periods Free account |
| (32.39%) | (30.24%) | (27.81%) | (24.89%) | ||
| (23.31%) | (22.12%) | (20.36%) | (18.34%) | ||
ROIC |
(45.60%) | (43.57%) | (44.34%) | (49.56%) | |
Return on Tangible Assets |
(30.71%) | (28.29%) | (25.87%) | (23.03%) | |
Average Days of Receivables |
108.82 | 116.43 | 109.25 | 98.97 | |
Free Cash Flow per Share |
(1.48) | (1.49) | (1.43) | (1.05) | |
Free Cash Flow |
(85.07) | (84.92) | (80.57) | (58.34) | |
Capital Expenditures |
(8.38) | (10.58) | (10.43) | (9.36) | |
| Other line items | |||||
Cash ROIC |
(14.20%) | (13.70%) | (12.49%) | (8.29%) | |
Accounts Receivable Turnover |
3.72 | 3.58 | 3.67 | 3.69 | |
Accounts Payable Turnover |
8.95 | 8.99 | 6.89 | 8.19 | |
Inventory Turnover |
1.68 | 1.68 | 1.66 | 1.76 | |
Average Days of Payables |
49.01 | 45.57 | 59.31 | 56.42 | |
Days of Inventory on Hand |
238.64 | 233.04 | 243.95 | 230.74 | |
Tax Rate |
— | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
22.89% | 23.36% | 23.71% | 23.14% | |
Selling, General and Administrative Expense of Revenue |
75.38% | 74.72% | 74.12% | 74.28% | |
Share Based Compensation of Revenue |
15.19% | 15.69% | 15.70% | 15.45% | |
Interest Coverage |
(34.71) | (32.88) | (30.91) | (28.96) | |
Operating CF/Net income |
0.67 | 0.68 | 0.68 | 0.51 | |
Depreciation/Fixed assets |
0.26 | 0.22 | 0.21 | 0.21 | |
Capex/Depreciation |
(1.05) | (1.50) | (1.57) | (1.46) | |
Revenue per Share |
6.15 | 5.91 | 5.70 | 5.55 | |
Operating CF per Share |
(1.34) | (1.30) | (1.24) | (0.88) | |
Capex per Share |
(0.15) | (0.19) | (0.18) | (0.17) | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.03 |
Columns are period end dates · fundamentals updated 4 Nov 2026